Factor V Leiden Mutation and Pregnancy

References

1. ↵
   Bloomenthal D, von Dadelszen P, Liston R, Magee L, Tsang P. The effect of factor V Leiden carriage on maternal and fetal health. CMAJ 2002; 167: 48–54.

   OpenUrlAbstract/FREE Full Text
2. ↵
   Macik BG, Rand JH, Konkle BA. Thrombophilia: what’s a practitioner to do? Hematology (Am Soc Hematol Educ Program) 2001; 322–38.
3. ↵
   Zoller B, Svensson PJ, He X, Dahlback B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521–4.
4. ↵
   Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64–7.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   Bauer KA, Rosendaal FR, Heit JA. Hypercoagulability: too many tests, too much conflicting data. Hematology (Am Soc Hematol Educ Program) 2002; 353–68.
6. ↵
   Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133–4.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361: 901–8.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   Dizon-Townson D, Nelson LM, Jahn G, Varner MW, Ward K. The incidence of factor V Leiden mutation in an obstetric population and its relationship to deep vein thombosis. Am J Obstet Gynecol 1997; 176: 883–6.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342: 374–80.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    Anticoagulation with low- molecular-weight heparin during pregnancy. ACOG Committee Opinion #221. ACOG 1998. Washington (DC): American College of Obstetricians and Gynecologists; 1998.
11. ↵
    Cavenaugh JD, Colvin BT. Guidelines for the management of thrombophilia. Postgrad Med J 1996; 72: 87–94.

    OpenUrlAbstract/FREE Full Text
12. ↵
    Hirsch J, Dalen JE, Guyatt G. The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. Chest 2001; 119: 122S–131S.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    Verstraete M, Prentic CRM, Samana M, Verhaeghe R. A European view on the North American fifth consensus on antithrombotic therapy. Chest 2000; 117: 1775–70.

    OpenUrl
14. ↵
    Barger AP, Hurley R. Evaluation of the hypercoagulable state: whom to screen, how to test and treat. Postgrad Med J 2000; 108: 59–66.

    OpenUrl
15. ↵
    Ghermann RB, Goodwin TM. Obstetrical implications of activated protein C resistance and factor V Leiden mutation. Obstet Gynecol Surv 2000; 55: 117–22.

    OpenUrlCrossRefPubMed
16. ↵
    Younnis JS, Ohel G, Brenner B, et al. The effect of thromboprophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation. BJOG 2000; 107: 415–9.

    OpenUrlPubMed
17. ↵
    Thromboembolism in pregnancy. ACOG Practice Bulletin no. 19. Washington (DC): American College of Obstetricians and Gynecologists; 2000.